Compare Adaptive Biotechnologies Corp (ADPT) vs GE Aerospace (GE) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs GE Aerospace — how do they compare? Adaptive Biotechnologies Corp trades at $19.98 (market cap $3.33B), while GE Aerospace trades at $356.69 (market cap $382.88B). The key difference: GE Aerospace is far larger — about 115× Adaptive Biotechnologies Corp's market cap, and GE Aerospace pays a 0.51% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | GE | |
|---|---|---|
Market Cap | $3.33B | $382.88B |
Sector | Health | Industrials |
52-Week High | $22.37 | $378.68 |
52-Week Low | $10.24 | $247.05 |
Enterprise Value | $3.19B | $392.18B |
Dividend Yield | — | 0.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
GE trades at $378.68, up 0.31% today, with a bullish technical signal from moving averages and strong support at $375. The company reported three consecutive quarterly earnings beats, with Q1 2026 EPS of $1.86 exceeding expectations. Revenue grew to $45.86 billion in 2025, while net income margin improved to 17.86%. Recent news highlights robust order growth in aerospace and defense contracts, including a U.S. Air Force engine development deal announced May 19, 2026.
Outlook remains positive with a consensus price target of $394.33, though high valuation ratios (P/E 47.04) and rising debt levels pose risks. Aerospace demand and defense contracts support growth, but investors should monitor execution on expansion investments and macroeconomic pressures on aviation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About GE Aerospace
General Electric Company is a globally diversified technology and financial services company. The Company's products and services include aircraft engines, power generation, water processing, and household appliances to medical imaging, business and consumer financing, and industrial products.
Read more on GE →
